C-02 Wendy Chu Optimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs Thursday 8:30-8:55 |
C-03 Selma El Messaoudi Mechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections Thursday 8:55-9:20 |
C-04 Julie Dudasova Logistic regression-based approach to assess heterogeneity in vaccine efficacy using immunogenicity measurements in phase 3 clinical trials Thursday 9:20-9:45 |